Gabapentin enacarbil (BioDeep_00000179289)
human metabolite blood metabolite
代谢物信息卡片
化学式: C16H27NO6 (329.1838)
中文名称: 1-[[[[1-(2-甲基-1-氧代丙氧基)乙氧基]甲酰]氨基]甲基]环己烷乙酸
谱图信息:
最多检出来源 Homo sapiens(blood) 91.67%
分子结构信息
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
InChI: InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)
描述信息
C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic
同义名列表
10 个代谢物同义名
2-(1-{[({1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl)amino]methyl}cyclohexyl)acetic acid; 1-(((alpha-Isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid; Gabapentinum enacarbilum; Gabapentina enacarbilo; Gabapentine enacarbil; Gabapentin enacarbil; XP-13512; Horizant; XP 13512; XP13512
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:68840
- PubChem: 9883933
- HMDB: HMDB0252567
- DrugBank: DB08872
- ChEMBL: CHEMBL1628502
- Wikipedia: Gabapentin_enacarbil
- chemspider: 8059607
- CAS: 478296-72-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Ritu Lal, Aaron Ellenbogen, Barry Gidal. Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From 6 Phase I Studies.
Therapeutic drug monitoring.
2022 06; 44(3):448-454. doi:
10.1097/ftd.0000000000000935. [PMID: 34726199] - Chao Chen, James Upward, Thangam Arumugham, Brendt Stier, Maria Davy. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison.
Clinical therapeutics.
2015 Feb; 37(2):349-57. doi:
10.1016/j.clinthera.2014.10.015. [PMID: 25467190] - R Norman Harden, Roy Freeman, Michelle Rainka, Lixin Zhang, Chris Bell, Alienor Berges, Chao Chen, Ole Graff, Kathleen Harding, Setrina Hunter, Sarah Kavanagh, Caryl Schwartzbach, Samantha Warren, Carrie McClung. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders.
Pain medicine (Malden, Mass.).
2013 Dec; 14(12):1918-32. doi:
10.1111/pme.12227. [PMID: 24102928] - Chao Chen. Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil.
European journal of clinical pharmacology.
2013 Oct; 69(10):1809-17. doi:
10.1007/s00228-013-1545-1. [PMID: 23743781] - Ritu Lal, Juthamas Sukbuntherng, Wendy Luo, James Tovera, Marie Liesse Lassauzet, Kenneth C Cundy. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.
Journal of clinical pharmacology.
2013 Jan; 53(1):29-40. doi:
10.1177/0091270012439209. [PMID: 23400741] - Stefano de Biase, Giovanni Merlino, Simone Lorenzut, Mariarosaria Valente, Gian Luigi Gigli. ADMET considerations for restless leg syndrome drug treatments.
Expert opinion on drug metabolism & toxicology.
2012 Oct; 8(10):1247-61. doi:
10.1517/17425255.2012.708023. [PMID: 22808933] - Ritu Lal, Aaron Ellenbogen, Dan Chen, Katie Zomorodi, Harisha Atluri, Wendy Luo, James Tovera, Janet Hurt, Daniel Bonzo, Marie-Liesse Lassauzet, Amanda Vu, Kenneth C Cundy. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.
Clinical neuropharmacology.
2012 Jul; 35(4):165-73. doi:
10.1097/wnf.0b013e318259eac8. [PMID: 22664749] - Ritu Lal, Juthamas Sukbuntherng, Wendy Luo, Dan Chen, Robin Blumenthal, Judy Ho, Kenneth C Cundy. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Clinical therapeutics.
2012 Jan; 34(1):201-13. doi:
10.1016/j.clinthera.2011.12.004. [PMID: 22206794] - R Lal, J Sukbuntherng, J Ho, K C Cundy. A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers.
International journal of clinical pharmacology and therapeutics.
2011 Feb; 49(2):109-15. doi:
10.5414/cpp49109. [PMID: 21255527] - Kenneth C Cundy, Russell Branch, Tania Chernov-Rogan, Tracy Dias, Toño Estrada, Karin Hold, Kerry Koller, Xiaoli Liu, Adam Mann, Matt Panuwat, Stephen P Raillard, Shubhra Upadhyay, Quincey Q Wu, Jia-Ning Xiang, Hui Yan, Noa Zerangue, Cindy X Zhou, Ronald W Barrett, Mark A Gallop. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.
The Journal of pharmacology and experimental therapeutics.
2004 Oct; 311(1):315-23. doi:
10.1124/jpet.104.067934. [PMID: 15146028] - Kenneth C Cundy, Thamil Annamalai, Lin Bu, Josephine De Vera, Jenny Estrela, Wendy Luo, Payal Shirsat, Allan Torneros, Fenmei Yao, Joan Zou, Ronald W Barrett, Mark A Gallop. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys.
The Journal of pharmacology and experimental therapeutics.
2004 Oct; 311(1):324-33. doi:
10.1124/jpet.104.067959. [PMID: 15146029]
